Yuanzhang Fang

Yuanzhang Fang

Auto-generated profile, based on publicly available information

Yuanzhang Fang

Department of Medical and Molecular Genetics

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 May 2021 in Journal of Clinical Investigation
Verified
Journal Article
Closed access
PDF file
HXHanchen Xu
Hanchen Xu
KJKevin Van der Jeught
Kevin Van der Jeught
ZZZhuolong Zhou
Zhuolong Zhou
LZLu Zhang
Lu Zhang
TYTao Yu
Tao Yu
XLXiongbin Lu
Xiongbin Lu
One of the primary mechanisms of tumor cell immune evasion is the loss of antigenicity, which arises due to lack of immunogenic tumor antigens as well as dysregulation of the antigen processing machinery. In a screen for small-molecule compounds from herbal medicine that potentiate T cell–mediated cytotoxicity, we identified atractylenolide I (ATT-I), which substantially promotes tumor antigen presentation of both human and mouse colorectal cancer (CRC) cells and thereby enhances the cytotoxic response of CD8+ T cells. Cellular thermal shift assay (CETSA) with multiplexed quantitative mass spectrometry identified the proteasome 26S subunit non–ATPase 4 (PSMD4), an essential component of the immunoproteasome complex, as a primary target protein of ATT-I. Binding of ATT-I with PSMD4 augments the antigen-processing activity of immunoproteasome, leading to enhanced MHC-I–mediated antigen presentation on cancer cells. In syngeneic mouse CRC models and human patient–derived CRC organoid models, ATT-I treatment promotes the cytotoxicity of CD8+ T cells and thus profoundly enhances the efficacy of immune checkpoint blockade therapy. Collectively, we show here that targeting the function of immunoproteasome with ATT-I promotes tumor antigen presentation and empowers T cell cytotoxicity, thus elevating the tumor response to immunotherapy.

4 January 2021 in Journal of Clinical Investigation
Verified
Journal Article
Closed access
PDF file
YFYuanzhang Fang
Yuanzhang Fang
LWLifei Wang
Lifei Wang
CWChanglin Wan
Changlin Wan
YSYifan Sun
Yifan Sun
KJKevin Van der Jeught
Kevin Van der Jeught
XZXinna Zhang
Xinna Zhang
Immune evasion is a pivotal event in tumor progression. To eliminate human cancer cells, current immune checkpoint therapy is set to boost CD8+ T cell–mediated cytotoxicity. However, this action is eventually dependent on the efficient recognition of tumor-specific antigens via T cell receptors. One primary mechanism by which tumor cells evade immune surveillance is to downregulate their antigen presentation. Little progress has been made toward harnessing potential therapeutic targets for enhancing antigen presentation on the tumor cell. Here, we identified MAL2 as a key player that determines the turnover of the antigen-loaded MHC-I complex and reduces the antigen presentation on tumor cells. MAL2 promotes the endocytosis of tumor antigens via direct interaction with the MHC-I complex and endosome-associated RAB proteins. In preclinical models, depletion of MAL2 in breast tumor cells profoundly enhanced the cytotoxicity of tumor-infiltrating CD8+ T cells and suppressed breast tumor growth, suggesting that MAL2 is a potential therapeutic target for breast cancer immunotherapy.

20 January 2016 in Nature Communications
Verified
Journal Article
Open access
PDF file
SCSoyoung Choi
Soyoung Choi
ZCZhengming Chen
Zhengming Chen
LTLaura H. Tang
Laura H. Tang
YFYuanzhang Fang
Yuanzhang Fang
SSSandra J. Shin
Sandra J. Shin
YDYi-Chieh Nancy Du
Yi-Chieh Nancy Du
Bcl-xL suppresses mitochondria-mediated apoptosis and is frequently overexpressed in cancer to promote cancer cell survival. Bcl-xL also promotes metastasis. However, it is unclear whether this metastatic function is dependent on its anti-apoptotic activity in the mitochondria. Here we demonstrate that Bcl-xL promotes metastasis independent of its anti-apoptotic activity. We show that apoptosis-defective Bcl-xL mutants and an engineered Bcl-xL targeted to the nucleus promote epithelial–mesenchymal transition, migration, invasion and stemness in pancreatic neuroendocrine tumour (panNET) and breast cancer cell lines. However, Bcl-xL proteins targeted to the mitochondria or outside of the nucleus do not have these functions. We confirm our findings in spontaneous and xenograft mouse models. Furthermore, Bcl-xL exerts metastatic function through epigenetic modification of the TGFβ promoter to increase TGFβ signalling. Consistent with these findings, we detect nuclear Bcl-xL in human metastatic panNETs. Taken together, the metastatic function of Bcl-xL is independent of its anti-apoptotic activity and its residence in the mitochondria.

21 December 2017 in The FASEB Journal
Verified
Journal Article
Open access
PDF file
ZYZhiying Yue
Zhiying Yue
ZYZengjin Yuan
Zengjin Yuan
LZLi Zeng
Li Zeng
YWYing Wang
Ying Wang
LLLi Lai
Li Lai
MLMingyao Liu
Mingyao Liu
The fourth member of the leucine‐rich repeat‐containing GPCR family (LGR4, frequently referred to as GPR48) and its cognate ligands, R‐spondins (RSPOs) play crucial roles in the development of multiple organs as well as the survival of adult stem cells by activation of canonical Wnt signaling. Wnt/β‐catenin signaling acts to regulate breast cancer; however, the molecular mechanisms determining its spatiotemporal regulation are largely unknown. In this study, we identified LGR4 as a master controller of Wnt/β‐catenin signaling‐mediated breast cancer tumorigenesis, metastasis, and cancer stem cell (CSC) maintenance. LGR4 expression in breast tumors correlated with poor prognosis. Either Lgr4 haploinsufficiency or mammary‐specific deletion inhibited mouse mammary tumor virus (MMTV)‐ PyMT ‐ and MMTV‐ Wnt1 ‐driven mammary tumorigenesis and metastasis. Moreover, LGR4 down‐regulation decreased in vitro migration and in vivo xenograft tumor growth and lung metastasis. Furthermore, Lgr4 deletion in MMTV‐Wnt1 tumor cells or knockdown in human breast cancer cells decreased the number of functional CSCs by ~90%. Canonical Wnt signaling was impaired in LGR4 ‐deficient breast cancer cells, and LGR4 knockdown resulted in increased E‐cadherin and decreased expression of N‐cadherin and snail transcription factor ‐2 ( SNAI2 ) (also called SLUG ), implicating LGR4 in regulation of epithelial–mesenchymal transition. Our findings support a crucial role of the Wnt signaling component LGR4 in breast cancer initiation, metastasis, and breast CSCs.—Yue, Z., Yuan, Z., Zeng, L., Wang, Y., Lai, L., Li, J., Sun, P., Xue, X., Qi, J., Yang, Z., Zheng, Y., Fang, Y., Li, D., Siwko, S., Li, Y., Luo, J., Liu, M. LGR4 modulates breast cancer initiation, metastasis, and cancer stem cells. FASEB J. 32, 2422–2437 (2018). www.fasebj.org

24 November 2012 in JNCI: Journal of the National Cancer Institute
Verified
Journal Article
Open access
PDF file
YFYuanzhang Fang
Yuanzhang Fang
YCYihua Chen
Yihua Chen
LYLinxi Yu
Linxi Yu
CZCong Zheng
Cong Zheng
YQYa Qi
Ya Qi
MLMingyao Liu
Mingyao Liu
Transforming growth factor beta (TGFβ), which is implicated in metastasis to various organs in breast cancer, is a potential target for new antitumor metastasis drugs. To identify specific inhibitors of TGFβ receptor 1 (TGFβR1) in breast cancer metastasis, a virtual library of more than 400000 different compounds was screened by molecular docking modeling and confirmed with Smad-binding element luciferase and TGFβR1 kinase assays. Affymetrix GeneChip expression analysis of mRNA levels and real-time polymerase chain reaction were performed to determine expression changes of TGFβ-mediated, metastasis-associated genes in breast cancer cells after treatment with the small-molecule inhibitor YR-290. YR-290 was also examined for its effects on breast cancer migration, invasion, and metastasis using transwell and epithelial-to-mesenchymal transition (EMT) assays in vitro and three different mouse (BALB/c and NU/NU nude) models (n = 10 per group). Kaplan–Meier analyses were used to assess survival. All statistical tests were two-sided. YR-290 interacted with the kinase domain of TGFβR1, abrogated kinase activity (half maximal inhibitory concentration = 137nM, 95% confidence interval = 126.4 to 147.6nM) and inhibited the TGFβ-mediated downstream signaling pathway and metastasis-associated genes in breast cancer cells. YR-290 inhibited TGFβ-modulated breast cancer cell migration and invasion. In tumor metastasis mouse models, YR-290 almost completely blocked cancer metastasis. Numbers of lung tumor nodules of mice treated with 1mg/kg and 5mg/kg YR-290 were reduced by 74.93% (95% confidence interval = 61.45% to 88.41%) and 94.93% (95% confidence interval = 82.13% to 100%), respectively, compared with control mice. Treatment with YR-290 also statistically significantly prolonged the survival of tumor-bearing mice. YR-290 is a novel inhibitor of tumor metastasis that works by blocking TGFβ signaling pathways.

27 January 2014 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
CZCong Zheng
Cong Zheng
YFYuanzhang Fang
Yuanzhang Fang
WTWeiguang Tong
Weiguang Tong
GLGuoliang Li
Guoliang Li
HWHaigang Wu
Haigang Wu
YCYihua Chen
Yihua Chen